TuHURA Biosciences (HURA) Non-Current Debt (2011 - 2025)

TuHURA Biosciences' (HURA) quarterly Non-Current Debt came in at $592000.0 in Q4 2025, little changed quarter-over-quarter from $592000.0 in Q3 2025.

TuHURA Biosciences (HURA) Non-Current Debt (2011 - 2025) Analysis & Trends

TuHURA Biosciences' Non-Current Debt history runs 7 years deep, the most recent figure standing at $592000.0 for Q4 2025.

On a quarterly basis, Non-Current Debt changed N/A year-over-year to $592000.0 in Q4 2025; TTM through Dec 2025 was $592000.0, a N/A change from a year earlier, with the FY2025 full-year figure at $592000.0, changed N/A from the prior year.
Non-Current Debt held at $592000.0 in Q4 2025 per HURA's latest filing, from $592000.0 in the prior quarter.
Across five years, Non-Current Debt topped out at $592000.0 in Q3 2025 and bottomed at $503000.0 in Q1 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-	-
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-	105.94 Mn
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn	842.92 Mn
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn	1.99 Bn
7	Belite Bio	62.72 Bn	62.72 Bn	-	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn	-
9	Revolution Medicines	37.35 Bn	37.35 Bn	-	-
10	TuHURA Biosciences	132.62 Mn	132.62 Mn	-	-

Download Data